346 related articles for article (PubMed ID: 17963805)
21. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.
Ismail A; El Hassan AM; Kemp K; Gasim S; Kadaru AE; Moller T; Kharazmi A; Theander TG
J Pathol; 1999 Dec; 189(4):615-22. PubMed ID: 10629566
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel.
Wortmann G; Miller RS; Oster C; Jackson J; Aronson N
Clin Infect Dis; 2002 Aug; 35(3):261-7. PubMed ID: 12115091
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial.
Reithinger R; Mohsen M; Wahid M; Bismullah M; Quinnell RJ; Davies CR; Kolaczinski J; David JR
Clin Infect Dis; 2005 Apr; 40(8):1148-55. PubMed ID: 15791515
[TBL] [Abstract][Full Text] [Related]
24. Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate.
Solomon M; Baum S; Barzilai A; Pavlotsky F; Trau H; Schwartz E
J Eur Acad Dermatol Venereol; 2009 Oct; 23(10):1189-92. PubMed ID: 19298486
[TBL] [Abstract][Full Text] [Related]
25. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran.
Mohebali M; Khamesipour A; Mobedi I; Zarei Z; Hashemi-Fesharki R
Vaccine; 2004 Sep; 22(29-30):4097-100. PubMed ID: 15364462
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
27. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis.
Llanos-Cuentas A; Calderón W; Cruz M; Ashman JA; Alves FP; Coler RN; Bogatzki LY; Bertholet S; Laughlin EM; Kahn SJ; Beckmann AM; Cowgill KD; Reed SG; Piazza FM
Vaccine; 2010 Oct; 28(46):7427-35. PubMed ID: 20851080
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy in Kala-azar.
Singh NK; Jha TK; Singh IJ; Jha S
J Assoc Physicians India; 1995 May; 43(5):319-20. PubMed ID: 9081958
[TBL] [Abstract][Full Text] [Related]
29. Post kala-azar dermal leishmaniasis: the Kenyan experience.
Muigai R; Gachihi GS; Oster CN; Were JB; Nyakundi PM; Chunge CN; Kirigi G; Rashid JR
East Afr Med J; 1991 Oct; 68(10):801-6. PubMed ID: 1667521
[TBL] [Abstract][Full Text] [Related]
30. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
31. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
32. PCR for diagnosis and assessment of cure in kala-azar patients in Bangladesh.
Salam MA; Mondal D; Kabir M; Ekram AR; Haque R
Acta Trop; 2010 Jan; 113(1):52-5. PubMed ID: 19769932
[TBL] [Abstract][Full Text] [Related]
33. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
Veeken H; Ritmeijer K; Seaman J; Davidson R
Trop Med Int Health; 2000 May; 5(5):312-7. PubMed ID: 10886792
[TBL] [Abstract][Full Text] [Related]
34. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
Karki P; Koirala S; Parija SC; Hansdak SG; Das ML
Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
[TBL] [Abstract][Full Text] [Related]
35. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan.
Collin S; Davidson R; Ritmeijer K; Keus K; Melaku Y; Kipngetich S; Davies C
Clin Infect Dis; 2004 Mar; 38(5):612-9. PubMed ID: 14986243
[TBL] [Abstract][Full Text] [Related]
36. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
[TBL] [Abstract][Full Text] [Related]
37. The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: does ultraviolet light (UVB) radiation play a role?
Ismail A; Khalil EA; Musa AM; El Hassan IM; Ibrahim ME; Theander TG; El Hassan AM
Med Hypotheses; 2006; 66(5):993-9. PubMed ID: 16386855
[TBL] [Abstract][Full Text] [Related]
38. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
[TBL] [Abstract][Full Text] [Related]
39. Post kala azar dermal leishmaniasis in Sudan.
Kordofani YM; Nour YT; El-Hassan AM; Shalayel MH
East Mediterr Health J; 2001 Nov; 7(6):1061-4. PubMed ID: 15332749
[TBL] [Abstract][Full Text] [Related]
40. Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment.
el Hassan AM; Ghalib HW; Zijlstra EE; Eltoum IA; Satti M; Ali MS; Ali HM
Trans R Soc Trop Med Hyg; 1992; 86(3):245-8. PubMed ID: 1329273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
